Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥7,210 JPY
Change Today +70.00 / 0.98%
Volume 60.8K
4555 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
Frankfurt
As of 10:29 PM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

sawai pharmaceutical co ltd (4555) Snapshot

Open
¥7,240
Previous Close
¥7,140
Day High
¥7,240
Day Low
¥7,160
52 Week High
02/25/15 - ¥7,900
52 Week Low
08/8/14 - ¥5,630
Market Cap
275.0B
Average Volume 10 Days
205.9K
EPS TTM
¥382.28
Shares Outstanding
38.1M
EX-Date
09/28/15
P/E TM
18.9x
Dividend
¥110.00
Dividend Yield
1.46%
Current Stock Chart for SAWAI PHARMACEUTICAL CO LTD (4555)

Related News

No related news articles were found.

sawai pharmaceutical co ltd (4555) Related Businessweek News

No Related Businessweek News Found

sawai pharmaceutical co ltd (4555) Details

Sawai Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells, imports, and exports pharmaceutical products in Japan. The company offers prescription drugs in various formulations, such as tablets, oral dispersing tablets, capsules, granules, injections, tapes, ophthalmic/nasal solutions, syrups, etc. in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, chemotherapeutics, vitamins, anti-cancer, etc. The company also provides antihyperlipidemic agents, diabetes drugs, and OTC drugs. It serves dispensing pharmacies, clinics, DPC hospitals, hospitals, and others. The company was founded in 1929 and is headquartered in Osaka, Japan.

Founded in 1929

sawai pharmaceutical co ltd (4555) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sawai pharmaceutical co ltd (4555) Key Developments

Sawai Pharmaceutical Co. Ltd., Annual General Meeting, Jun 25, 2015

Sawai Pharmaceutical Co. Ltd., Annual General Meeting, Jun 25, 2015.

Sawai Pharmaceutical Co. Ltd. Declares Dividend for the Year Ended March 31, 2015, Payable on June 26, 2015; Provides Dividend Guidance for the Second Quarter and Full Year Ended March 31, 2016; Reports Unaudited Consolidated and Non Consolidated Earnings Results for the Year Ended March 31, 2015; Provides Earnings Guidance for Half Year and Full Year of Fiscal 2016

Sawai Pharmaceutical Co. Ltd. declared dividend of ¥55.00 per share for the year ended March 31, 2015, Payable on June 26, 2015. For the second quarter of fiscal 2016, the company expects to pay ¥55.00 per share. For the fiscal year ending March 31, 2016, the company expects to pay ¥55.00 per share. The company reported unaudited consolidated and non consolidated earnings results for the year ended March 31, 2015. For the period, on consolidated basis the company reported net sales of ¥105,454 million compared with ¥89,823 million for the same period last year. Operating income was ¥20,688 million compared with ¥19,090 million for the same period last year. Ordinary income was ¥20,619 million compared with ¥19,091 million for the same period last year. Net income was ¥14,053 million or ¥381.85 diluted per share compared with ¥12,192 million or ¥330.41 diluted per share for the same period last year. Cash flows from operating activities was ¥12,112 million compared with ¥13,422 million for the same period last year. For the period, on non consolidated basis the company reported net sales of ¥104,678 million compared with ¥88,969 million for the same period last year. Operating income was ¥20,248 million compared with ¥18,574 million for the same period last year. Ordinary income was ¥20,293 million compared with ¥18,669 million for the same period last year. Net income was ¥13,880 million or ¥377.16 diluted per share compared with ¥11,967 million or ¥324.29 diluted per share for the same period last year. The company provided earnings guidance for half year and full year of fiscal 2016. For the half year, the company expected net sales to be ¥58,700 million. Operating income to be ¥10,700 million. Ordinary income to be ¥10,600 million. Profit attributable to owners of parent to be ¥7,900 million and net income per share to be ¥214.89. For the full year year, the company expected net sales to be ¥124,000 million, perating income to be ¥22,000 million, ordinary income to be ¥21,700 million, profit attributable to owners of parent to be ¥15,500 million and net income per share to be ¥421.62.

Sawai Pharmaceutical Co. Ltd. to Report Fiscal Year 2015 Results on May 14, 2015

Sawai Pharmaceutical Co. Ltd. announced that they will report fiscal year 2015 results on May 14, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4555:JP ¥7,210.00 JPY +70.00

4555 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4555.
View Industry Companies
 

Industry Analysis

4555

Industry Average

Valuation 4555 Industry Range
Price/Earnings 18.3x
Price/Sales 2.4x
Price/Book 2.3x
Price/Cash Flow 19.0x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAWAI PHARMACEUTICAL CO LTD, please visit www.sawai.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.